FHTXFoghorn Therapeutics Inc.

$330M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M-55.3% YoY

Gross Profit

$8M100.0% margin

Operating Income

-$24M-305.5% margin

Net Income

-$19M-244.9% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

+13.4%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$308M

Total Liabilities

$337M

Stockholders' Equity

-$28M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$17M	-55.3%
Gross Profit	$8M	-$9M	+189.0%
Operating Income	-$24M	-$17M	-39.6%
Net Income	-$19M	-$14M	-33.3%

FHTX Q3 2024 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena